

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

CEPHALON, INC.	)	
	)	
<i>Plaintiff,</i>	)	
	)	
v.	)	Civil Action No. _____
	)	
INNOPHARMA, INC.	)	
	)	
<i>Defendant.</i>	)	
	)	

**COMPLAINT**

Cephalon, Inc. (“Cephalon” or “Plaintiff”) brings this action for patent infringement against Defendant InnoPharma, Inc. (“InnoPharma” or “Defendant”).

1. This is an action by Cephalon against InnoPharma for infringement of United States Patent No. 8,791,270 (“the ’270 patent”). This action arises out of InnoPharma’s filing of an Abbreviated New Drug Application (“ANDA”) seeking approval by the United States Food and Drug Administration (“FDA”) to sell generic versions of TREANDA<sup>®</sup>, Cephalon’s innovative treatment for chronic lymphocytic leukemia and non-Hodgkin’s lymphoma, prior to the expiration of the ’270 patent.

**THE PARTIES**

**Cephalon, Inc.**

2. Plaintiff Cephalon, Inc. is a corporation operating and existing under the laws of Delaware, with its principal place of business at 41 Moores Road, Frazer, Pennsylvania 19355. Cephalon is engaged in the business of research, development, manufacture, and sale of innovative pharmaceutical products throughout the world.

**InnoPharma, Inc.**

3. Upon information and belief, Defendant InnoPharma is a corporation organized and existing under the laws of the State of Delaware, with its principal place of business at 10 Knightsbridge Road, Piscataway, New Jersey 08854. InnoPharma can be served via its registered agent, The Corporation Trust Company, Corporation Trust Center, 1209 Orange Street, Wilmington, Delaware 19801.

**JURISDICTION AND VENUE**

**Subject Matter Jurisdiction**

4. This action for patent infringement arises under 35 U.S.C. § 271.

5. This Court has jurisdiction over the subject matter of this action pursuant to 28 U.S.C. §§ 1331 and 1338(a), and the Declaratory Judgment Act, 28 U.S.C §§ 2201 and 2202.

**Personal Jurisdiction Over InnoPharma**

6. Upon information and belief, this Court has personal jurisdiction over InnoPharma at least because InnoPharma: (1) is incorporated in Delaware and conducts business in this Judicial District; and (2) markets, distributes and/or sells generic drugs throughout the United States and within the State of Delaware and therefore purposefully avails itself of the privilege of conducting activities within the State of Delaware. InnoPharma has also committed, or aided, abetted, contributed to and/or participated in the commission of, the tortious action of patent infringement that has led to foreseeable harm and injury to Cephalon, which manufactures TREANDA<sup>®</sup>, for sale and use throughout the United States, including the State of Delaware.

7. Upon information and belief, this Court also has personal jurisdiction over InnoPharma because InnoPharma previously has been sued in this Judicial District and did not challenge this Court's exertion of personal jurisdiction over it, including in related co-pending

actions. *See Spectrum Pharm. v. InnoPharma, Inc.*, C.A. No. 12-00260 (D. Del); *Cumberland Pharm. v. InnoPharma, Inc.*, C.A. No. 12-00618 (D. Del).

8. On information and belief, this Court also personal jurisdiction over InnoPharma because InnoPharma did not challenge this Court's exercise of personal jurisdiction over it for purposes of litigating allegations of patent infringement involving the ANDA that is the subject matter of this lawsuit. *See Cephalon, Inc. v. InnoPharma, Inc.*, C.A. No. 14-590-GMS (D. Del.); *Cephalon, Inc. v. InnoPharma, Inc.*, C.A. No. 13-2081-GMS (D. Del.).

### **Venue**

9. Venue is proper in this Judicial District under 28 U.S.C. §§ 1391 and 1400(b).

## **BACKGROUND**

### **The '270 Patent**

10. The '270 patent, entitled "Bendamustine Pharmaceutical Compositions," was duly and lawfully issued on July 29, 2014 to inventors Jason Edward Brittain and Joe Craig Franklin.

11. The named inventors of the '270 patent assigned their rights in the '270 patent to Cephalon.

12. Cephalon is the sole owner by assignment of all rights, title and interest in the '270 patent.

13. Shortly after the '270 patent issued, Cephalon listed the '270 patent in FDA publication "Approved Drug Products with Therapeutic Equivalence Evaluations," commonly referred to as "the Orange Book" ("Orange Book"), with respect to TREANDA<sup>®</sup>.

14. The '270 patent will expire on January 12, 2026. A true and accurate copy of the '270 patent is attached hereto as Exhibit A.

**The TREANDA<sup>®</sup> Drug Product**

15. Cephalon researched, developed, applied for and obtained FDA approval to manufacture, sell, promote and/or market bendamustine hydrochloride products known as TREANDA<sup>®</sup>.

16. Cephalon has been selling, promoting, distributing and marketing TREANDA<sup>®</sup> in the United States since 2008.

17. TREANDA<sup>®</sup> is indicated to treat chronic lymphocytic leukemia and non-Hodgkin's lymphoma.

18. Cephalon holds New Drug Application No. 22249 and No. 22303 under Section 505(a) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 355(a), for multiple TREANDA<sup>®</sup> products used for treating chronic lymphocytic leukemia and non-Hodgkin's lymphoma.

**The InnoPharma ANDA**

19. InnoPharma filed with FDA an Abbreviated New Drug Application under 21 U.S.C. § 355(j) seeking approval to manufacture, use, offer for sale, sell in and import into the United States bendamustine hydrochloride powder for IV (infusion), 25 mg/vial and 100 mg/vial ("InnoPharma's Bendamustine Product") prior to the expiration of the '270 patent.

20. FDA assigned the ANDA for InnoPharma's Bendamustine Product the number 205476.

**The Ongoing Litigations**

21. In connection with its ANDA, InnoPharma filed with FDA, pursuant to 21 U.S.C. § 355(j)(2)(B)(iv), a certification alleging that the claims of other Cephalon patents, United States Patent No. 8,445,524 ("the '524 patent"), United States Patent No. 8,436,190 ("the '190

patent”), and United States Patent No. 8,609,863 (“the ’863 patent”), are invalid, unenforceable and/or would not be infringed by the manufacture, use, importation, sale or offer for sale of InnoPharma’s Bendamustine Product (“InnoPharma’s Paragraph IV Certification”).

22. By letter dated November 8, 2013, InnoPharma notified Cephalon that it had filed ANDA No. 205476 seeking approval to market InnoPharma’s Bendamustine Product prior to the expiration of the ’524 and ’190 patents (“InnoPharma’s First Notice Letter”). InnoPharma notified Cephalon by letter dated March 26, 2014 that it had filed an amendment to ANDA No. 205476 seeking approval to market InnoPharma’s Bendamustine Product prior to the expiration of the ’863 patent (“InnoPharma’s Second Notice Letter”).

23. Pursuant to an Offer of Confidential Access, Cephalon received portions of the ANDA filed by InnoPharma, and Cephalon reviewed those portions of the ANDA.

24. On December 23, 2013 and May 9, 2014, respectively, Cephalon sued InnoPharma for patent infringement of the ’524 patent and the ’190 patent and the ’863 patent in the District of Delaware. *See Cephalon, Inc. v. InnoPharma, Inc.*, C.A. No. 14-590-GMS (D. Del.); *Cephalon, Inc. v. InnoPharma, Inc.*, C.A. No. 13-2081-GMS (D. Del.). Those two actions respectively were commenced before the expiration of forty-five days from the date of receipt of InnoPharma’s First Notice Letter and InnoPharma’s Second Notice Letter, which effectively stayed FDA from granting final approval to InnoPharma’s ANDA No. 205476 prior to the expiration of 30 months from the date InnoPharma’s First Notice Letter was received by Cephalon.

**COUNT I: INFRINGEMENT OF U.S. PATENT NO. 8,791,270 BY INNOPHARMA**

25. The allegations of the preceding paragraphs 1–24 are re-alleged and incorporated herein by reference.

26. The '270 patent issued on July 29, 2014, and Cephalon timely listed the '270 patent in the Orange Book.

27. Cephalon notified InnoPharma of the issuance of the '270 patent before filing this action.

28. The use of InnoPharma's Bendamustine Product is covered by one or more claims of the '270 patent.

29. The commercial manufacture, use, offer for sale, sale, marketing, distribution and/or importation of InnoPharma's Bendamustine Product would infringe one or more claims of the '270 patent.

30. Under 35 U.S.C. § 271(e)(2)(A), InnoPharma's submission to FDA of the InnoPharma ANDA to obtain approval for InnoPharma's Bendamustine Product constitutes an act of infringement, and if approved, the commercial manufacture, use, offer to sell, sale, or importation of InnoPharma's Bendamustine Product containing bendamustine hydrochloride, would infringe one or more claims of the '270 patent.

31. On information and belief, InnoPharma's Bendamustine Product contains the same active pharmaceutical ingredient, bendamustine hydrochloride, as that used in Cephalon's TREANDA<sup>®</sup> products and claimed in the '270 patent.

32. On information and belief, InnoPharma's Bendamustine Product is the pharmaceutical composition of bendamustine hydrochloride, containing less than or equal to 4.0% (area percent of bendamustine) of bendamustine degradants, recited in one or more claims of the '270 patent.

33. On information and belief, InnoPharma's Bendamustine Product is the pharmaceutical composition of bendamustine hydrochloride, containing not more than the amount of the HP1 degradant, recited in one or more claims of the '270 patent.

34. On information and belief, InnoPharma's Bendamustine Product infringes one or more claims of the '270 patent.

35. On information and belief, InnoPharma plans and intends to, and will, infringe the '270 patent immediately and imminently upon approval of the InnoPharma ANDA.

36. On information and belief, InnoPharma, under 35 U.S.C. § 271(b), acted in concert, actively supported, participated in, encouraged, and/or induced the infringement of one or more claims of the '270 patent.

37. On information and belief, InnoPharma plans and intends to, and will, actively induce infringement of the '270 patent when the InnoPharma ANDA is approved, and plan and intend to, and will, do so immediately and imminently upon approval.

38. On information and belief, InnoPharma knows that InnoPharma's Bendamustine Product is especially made or adapted for use in infringing the '270 patent and that InnoPharma's Bendamustine Product is not suitable for substantial non-infringing uses. On information and belief, under 35 U.S.C. § 271(c), InnoPharma plans and intends to, and will, contribute to the infringement of the '270 patent immediately and imminently upon approval of the InnoPharma ANDA.

39. The foregoing actions by InnoPharma constitute and/or would constitute infringement of the '270 patent, active inducement of infringement of the '270 patent and/or contribution to the infringement by others of the '270 patent.

40. On information and belief, InnoPharma acted without a reasonable basis for believing that it would not be liable for infringing the '270 patent, actively inducing infringement of the '270 patent and/or contributing to the infringement by others of the '270 patent.

41. Cephalon will be substantially and irreparably harmed by InnoPharma's infringing activities unless the Court enjoins those activities. Cephalon will have no adequate remedy at law if InnoPharma is not enjoined from the commercial manufacture, use, offer to sell, sale in and importation into the United States of InnoPharma's Bendamustine Product.

42. InnoPharma's activities render this case an exceptional one, and Cephalon is entitled to an award of its reasonable attorneys' fees under 35 U.S.C. § 285.

**COUNT II: DECLARATORY JUDGMENT OF  
INFRINGEMENT OF U.S. PATENT NO. 8,791,270 BY INNOPHARMA**

43. The allegations of the proceeding paragraphs 1–42 are re-alleged and incorporated herein by reference.

44. On information and belief, InnoPharma plans to begin manufacturing, marketing, selling, offering to sell and/or importing InnoPharma's Bendamustine Product soon after FDA approval of the InnoPharma ANDA.

45. Such conduct will constitute direct infringement of one or more claims on the '270 patent under 35 U.S.C. § 271(a), inducement of infringement of the '270 patent under 35 U.S.C. § 271(b), and contributory infringement under 35 U.S.C. § 271(c).

46. InnoPharma's infringing patent activity complained of herein is imminent and will begin following FDA approval of the InnoPharma ANDA.

47. As a result of the foregoing facts, there is a real, substantial, and continuing justiciable controversy between Plaintiff and InnoPharma as to liability for the infringement of



the '270 patent. InnoPharma's actions have created in Plaintiff a reasonable apprehension of irreparable harm and loss resulting from InnoPharma's threatened imminent actions.

48. On information and belief, InnoPharma will knowingly and willfully infringe the '270 patent.

49. Cephalon will be substantially and irreparably harmed by InnoPharma's infringing activities unless the Court enjoins those activities.

**PRAYER FOR RELIEF**

WHEREFORE, Cephalon respectfully request the following relief:

- a. a judgment that the '270 patent is valid and enforceable;
- b. a judgment that InnoPharma's submission of the InnoPharma ANDA No. 205476 was an act of infringement of one or more claims of the '270 patent and that the making, using, offering to sell, selling, marketing, distributing, or importing of InnoPharma's Bendamustine Products prior to the expiration of the '270 patent will infringe, actively induce infringement and/or contribute to the infringement of one or more claims of the 270 patent;
- c. an Order pursuant to 35 U.S.C. § 271(e)(4)(A) providing that the effective date of any FDA approval of the InnoPharma ANDA No. 205476 or any product or compound the use of which infringes the '270 patent shall be a date that is not earlier than the expiration of the '270 patent;
- d. an Order pursuant to 35 U.S.C. § 271(e)(4)(B) permanently enjoining InnoPharma and all persons acting in concert with InnoPharma from commercially manufacturing, using, offering for sale, selling, marketing, distributing, or importing InnoPharma's Bendamustine Products, or any product or compound the use of which infringes the '270 patent, or inducing or contributing to the infringement of the '270 patent, until after the expiration of the '270 patent;

e. an Order pursuant to 35 U.S.C. § 283 permanently enjoining InnoPharma and all persons acting in concert with InnoPharma from commercially manufacturing, using, offering for sale, selling, marketing, distributing, or importing InnoPharma's Bendamustine Products, or any product or compound the use of which infringes the '270 patent, or inducing or contributing to the infringement of the '270 patent, until after the expiration of the '270 patent;

f. an Order enjoining InnoPharma and all persons acting in concert with InnoPharma from seeking, obtaining, or maintaining approval of the InnoPharma ANDA No. 205476 before the expiration of the '270 patent;

g. an award of Cephalon's damages or other monetary relief to compensate Cephalon if InnoPharma engages in the commercial manufacture, use, offer to sell, sale or marketing or distribution in, or importation into the United States of InnoPharma's Bendamustine Products, or any product or compound the use of which infringes the '270 patent, or the inducement or contribution of the foregoing, prior to the expiration of the '270 patent in accordance with 35 U.S.C. § 271(e)(4)(C);

h. an award of Cephalon's damages or other monetary relief to compensate Cephalon if InnoPharma engages in the commercial manufacture, use, offer to sell, sale or marketing or distribution in, or importation into the United States of InnoPharma's Bendamustine Products, or any product or compound the use of which infringes the '270 patent, or the inducement or contribution of the foregoing, prior to the expiration of the '270 patent;

i. a judgment that this is an exceptional case and awarding Cephalon its attorneys' fees under 35 U.S.C. § 285;

j. an award of Cephalon's reasonable costs and expenses in this action; and

k. an award of any further and additional relief to Cephalon as this Court deems just and proper.

Dated: September 25, 2014

BAYARD, P.A.

OF COUNSEL:

David M. Hashmall  
Calvin E. Wingfield Jr.  
GOODWIN PROCTER LLP  
The New York Times Building  
620 Eighth Avenue  
New York, NY 10018-1405  
(212) 813-8800

Daryl L. Wiesen  
Emily L. Rapalino  
Nicholas K. Mitrokostas  
Exchange Place  
Boston, MA 02109  
(617) 570-1000

/s/ Stephen B. Brauerman

Stephen B. Brauerman (sb4952)  
Vanessa R. Tiradentes (vt5398)  
Sara E. Bussiere (sb5725)  
222 Delaware Avenue, Suite 900  
Wilmington, DE 19801  
(302) 655-5000  
sbrauerman@bayardlaw.com  
vtiradentes@bayardlaw.com  
sbussiere@bayardlaw.com

*Attorneys for Plaintiff Cephalon, Inc.*